A novel, killed-virus nasal vaccinia virus vaccine

被引：37

作者：

Bielinska, Anna U. ^{[1
]}

Chepurnov, Alexander A. ^{[1
]}

Landers, Jeffrey J. ^{[1
]}

Janczak, Katarzyna W. ^{[1
]}

Chepurnova, Tatiana S. ^{[1
]}

Luker, Gary D. ^{[2
]}

Baker, James R., Jr. ^{[1
]}

机构：

[1] Univ Michigan, MNIMBS, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA

来源：

CLINICAL AND VACCINE IMMUNOLOGY | 2008年 / 15卷 / 02期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1128/CVI.00440-07

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 [免疫学];

摘要：

Live-virus vaccines for smallpox are effective but have risks that are no longer acceptable for routine use in populations at minimal risk of infection. We have developed a mucosal, killed-vaccinia virus (VV) vaccine based on antimicrobial nanoemulsion (NE) of soybean oil and detergent. Incubation of VV with 10% NE for at least 60 min causes the complete disruption and inactivation of VV. Simple mixtures of NE and VV (Western Reserve serotype) (VV/NE) applied to the nares of mice resulted in both systemic and mucosal anti-VV immunity, virus-neutralizing antibodies, and Th1-biased cellular responses. Nasal vaccination with VV/NE vaccine produced protection against lethal infection equal to vaccination by scarification, with 100% survival after challenge with 77 times the 50% lethal dose of live VV. However, animals protected with VV/NE immunization did after virus challenge have clinical symptoms more extensive than animals vaccinated by scarification. VV/NE-based vaccines are highly immunogenic and induce protective mucosal and systemic immunity without the need for an inflammatory adjuvant or infection with live virus.

引用

页码：348 / 358

页数：11

共 42 条

[1]

SELECTION OF RECOMBINANT VACCINIA VIRUSES ON THE BASIS OF PLAQUE-FORMATION [J].